is not required, as would be typical for organ transplants from other donors. Phase 1b/2a Data Presented at AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases Oryon’s lead program is currently being evaluated in an ongoing...
infants are treated with HEMANGEOL annually in the United States. The transaction is expected to be accretive to 2026 earnings and will be financed with the company’s cash on hand. Pierre Fabre will continue commercializing HEMANGEOL globally, and...
and expanding state regulations are dismantling the industry's long-standing "opacity premium." These forces make 2026 more than just another year of policy debate. They mark a structural shift where employer governance and market pressure converge...
(PD-1)/programmed death-ligand 1 (PD-L1) therapy. These data are being presented as a late-breaking oral abstract at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (abstract #LBA417) and are included in...
Confident proteoform characterization and eXd-enabled glycoproteomics on timsOmni The latest version OmniScape™ 2026b strengthens timsOmni proteoform workflows by integrating the novel OmniWave™ algorithm, which enables top-down sequencing and...
with no disease identified on his latest PET conducted 1 month after the administration of the fourth cycle (Feb 2026; Figure 2). Following the first three cycles of 67Cu-SAR-bisPSMA, the participant exhibited mild (Grade 1) related AEs, most of...
-30.0 mL to -50.0 mL).2 PureTech’s Founded Entity, Celea Therapeutics, intends to finalize financing in the first half of 2026 to support the initiation of the Phase 3 SURPASS-IPF trial in the first half of 2026. SURPASS-IPF will compare...
community,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “The data presented at ECCO 2026 further demonstrate our leadership and long-standing commitment to raising standards of care in gastroenterology and to improving the...
HYD LLC has announced that registration is now open for the 5th International Congress on Deuterium Depletion (ICDD2026) in Budapest, Hungary, between 22 and 23 April 2026. About HYD LLC: HYD LLC for Cancer Research and Drug Development has been...
integrated, commercial biotechnology company, presented data on TONMYA™, which was investigated as TNX-102 SL, at the 2026 Non-Opioid Pain Therapeutics Summit, on January 29, 2026, in Boston, Massachusetts. A copy of the Company's presentation,...
provides increased access to compounded tirzepatide and semaglutide, perfectly timed to support Americans pursuing their 2026 health and wellness resolutions. As millions of Americans set ambitious weight loss goals for the new year, CoreAge Rx's...
retailing for $219.99. The product will also be available for purchase in select Target stores beginning February 16, 2026. The pump will be available through DME (Durable Medical Equipment) providers as an upgrade option. For more information...
in the global CRO industry and has served as Novotech Chairman since 2021. He commenced as Chairman and CEO on 1 January 2026. Reflecting Novotech’s increasingly international profile, Dr. Tharmaratnam will be based at the company’s new global...
syringe (PFS). The PFS presentation is expected to be available on the European market starting in the second quarter of 2026. About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to...
neuromodulation. Nia Therapeutics is preparing for first-in-human studies, with regulatory submissions planned for 2026. The initial study will focus on patients with memory loss resulting from moderate-to-severe traumatic brain injury. About Nia...
supporting weight loss in people living with obesity. We are really looking forward to the commercial launch of MOVIVA® in 2026,” says Marcus Felstead, Chief Commercial Officer at Erbe Elektromedizin. Register for the free webinar "Advancing...
referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major...
monitoring. KYZATREX will be available through multiple telehealth and traditional provider options in the first half of 2026.The availability of an oral testosterone option presents a convenient alternative to injectable or transdermal...
of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. “We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe. We will work closely with Biogen to...
candidate RLS-1496 in patients with actinic keratosis. The Gulf Cooperation Council (GCC) study is expected to begin in Q2 2026. “In our earliest meetings with the Hevolution team, we were convinced that Saudi Arabia and the GCC had the potential...
